Issue Highlights Clinical Gastroenterology and Hepatology Jonathan M. Buscaglia, MD, AGAF  Clinical Gastroenterology and Hepatology  Volume 14, Issue 10, Pages 1367-1370 (October 2016) DOI: 10.1016/j.cgh.2016.08.001 Copyright © 2016 AGA Institute Terms and Conditions

Figure 1 Significant dose-response association between EOT HBsAg level and clinical (A) and virologic (B) relapse in patients with negative HBeAg at the end of treatment. Clinical Gastroenterology and Hepatology 2016 14, 1367-1370DOI: (10.1016/j.cgh.2016.08.001) Copyright © 2016 AGA Institute Terms and Conditions

Figure 2 Cumulative probability to remain IC during follow-up given HBsAg at inclusion. *HBsAg 100–1000 IU/mL versus >1000 IU/mL: HR, 0.61; 95% CI, 0.3–1.2; P = .144. Two IC patients did not have further follow-up beyond Year 1. Clinical Gastroenterology and Hepatology 2016 14, 1367-1370DOI: (10.1016/j.cgh.2016.08.001) Copyright © 2016 AGA Institute Terms and Conditions

Figure 3 Meta-regression analysis. BMI (X axis) was plotted against the estimated pooled effect of the intervention on intrahepatic lipid level (SMD, Y axis). The more negative the SMD value, the more effective the intervention at lowering intrahepatic lipids. P = .037. This analysis was robust even after removing the outlier (Hallsworth et al24). Clinical Gastroenterology and Hepatology 2016 14, 1367-1370DOI: (10.1016/j.cgh.2016.08.001) Copyright © 2016 AGA Institute Terms and Conditions